Targeting the NLRP3/Caspase-1/GSDMD signaling axis, MSCs-Exo may establish a novel therapeutic paradigm for modulating intestinal inflammation and promoting tissue repair in IBD management. Here, NLRP3 is linked to inflammatory bowel disease.